An Analysis of the FALCON Trial
Matthew J. Ellis, MD, PhD, discusses the ongoing phase III FALCON trial.
Matthew J. Ellis, MD, PhD, professor, Department of Medicine, Oncology Division, Breast Oncology Section, Washington University School of Medicine in St. Louis, Missouri and the Siteman Cancer Center, discusses the ongoing phase III FALCON trial.
Clinical Pearls
- The FALCON trial is comparing anastrozole to the newly approved, high-dose fulvestrant (500mg) for patients with treatment-naïve metastatic breast cancer
- The rationale of the trial is to see if the high dose of fulvestrant will maintain disease control for a longer period of time than patients receiving anastrozole
- This is a registration trial and will alter the label of fulvestrant to include treatment-naïve advanced breast cancer
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
November 13th 2024During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO, discussed data from the DESTINY-Breast04 and DESTINY-Breast06 trials for HER2-low breast cancer in the second article of a 2-part series.
Read More
